Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Intravenous administration results in even more rapid excretion with little opportunity for liver storage
Genome-wide gene expression modulation studies
Products that list peptides high on the ingredient list (and not buried among fillers) tend to offer better value
27: A week after the FDA denied Venatorx Pharmaceuticals and Melinta Therapeutics New Drug Application for urinary tract infection (UTI) antibiotic cefepime-taniborbactam, competitor Allecra Therapeutics won approval of Exblifep in the same indication
US$ 22.10
US$ 22.22
US$ 26.48
